{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:00:51Z","timestamp":1792670451356,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T00:00:00Z","timestamp":1500508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.jbo.2017.09.001","type":"journal-article","created":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T14:01:00Z","timestamp":1505138460000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"special_numbering":"C","title":["The role of biomarkers in the management of bone-homing malignancies"],"prefix":"10.1016","volume":"9","author":[{"given":"Stella","family":"D\u2019Oronzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jbo.2017.09.001_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms17101674","article-title":"Cancer cell colonisation in the bone microenvironment","volume":"17","author":"Kan","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbo.2017.09.001_bib2","unstructured":"Cancer Research UK (CRUK) and National Cancer Intelligence Network (NCIN). CRUK BC statistics. \u3008http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/breast-cancer#KSe8ZK5GxJiqGX75.99\u3009. (Accessed February 11, 2017)."},{"key":"10.1016\/j.jbo.2017.09.001_bib3","unstructured":"CRUK. Cancer statistics. \u3008http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/prostate-cancer\/incidence#heading-One\u3009. Published 2013. (Accessed 11 February 2017)."},{"key":"10.1016\/j.jbo.2017.09.001_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/srep18670","article-title":"Natural history of non-small-cell lung cancer with bone metastases","volume":"5","author":"Santini","year":"2015","journal-title":"Sci. Rep."},{"issue":"10","key":"10.1016\/j.jbo.2017.09.001_bib5","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(04)01596-7","article-title":"Assessment of therapeutic response in patients with metastatic bone disease","volume":"5","author":"Clamp","year":"2004","journal-title":"Lancet Oncol."},{"issue":"Suppl. 8","key":"10.1016\/j.jbo.2017.09.001_bib6","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.jbo.2017.09.001_bib7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ctrv.2008.05.001","article-title":"Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions","volume":"34","author":"Coleman","year":"2008","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"10.1016\/j.jbo.2017.09.001_bib8","doi-asserted-by":"crossref","first-page":"djv360","DOI":"10.1093\/jnci\/djv360","article-title":"CAPG and GIPC1: BC biomarkers for bone metastasis development and treatment","volume":"108","author":"Westbrook","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jbo.2017.09.001_bib9","doi-asserted-by":"crossref","unstructured":"R. Coleman, A. Hall, R. Bell, D. Cameron, H. Marshall, J. Jean-Mairet, J. Tercero, F. Rojo, J. Albanell, R. Gomis, Impact of MAF gene amplification on disease recurrence and effects of adjuvant zoledronic acid in early breast cancer, in: Proceedings of San Antonio BC Symposium, Abstract P1-09-01, 2016.","DOI":"10.1158\/1538-7445.SABCS16-P1-09-01"},{"issue":"9","key":"10.1016\/j.jbo.2017.09.001_bib10","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1593\/neo.10610","article-title":"Evolving role of bone biomarkers in castration-resistant prostate cancer","volume":"12","author":"Brown","year":"2010","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.jbo.2017.09.001_bib11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00223-017-0259-2","article-title":"bone alkaline phosphatase and Tartrate-resistant acid phosphatase: potential co-regulators of bone mineralization","volume":"101","author":"Halling Linder","year":"2017","journal-title":"Calcif. Tissue Int."},{"issue":"1","key":"10.1016\/j.jbo.2017.09.001_bib12","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bone.2007.09.047","article-title":"Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading","volume":"42","author":"You","year":"2008","journal-title":"Bone"},{"issue":"8","key":"10.1016\/j.jbo.2017.09.001_bib13","first-page":"1353","article-title":"Physiology and pathophysiology of bone remodeling","volume":"45","author":"Raisz","year":"1999","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jbo.2017.09.001_bib14","series-title":"Osteoncology Textbook","first-page":"2","article-title":"Functional anatomy of bone","author":"Marotti","year":"2010"},{"key":"10.1016\/j.jbo.2017.09.001_bib15","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"50","author":"Roodman","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jbo.2017.09.001_bib16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ncpuro0995","article-title":"Androgen-deprivation-therapy-induced fractures in men with non metastatic prostate cancer: what do we really know?","volume":"5","author":"Higano","year":"2008","journal-title":"Nat. Clin. Pract. Urol."},{"key":"10.1016\/j.jbo.2017.09.001_bib17","series-title":"A Treatise on Tumours","author":"Ewing","year":"1928"},{"issue":"5897","key":"10.1016\/j.jbo.2017.09.001_bib18","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1126\/science.1164853","article-title":"Cancer. The metastasis cascade","volume":"321","author":"Klein","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.jbo.2017.09.001_bib19","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10555-013-9420-1","article-title":"The pre-metastatic niche: finding common ground","volume":"32","author":"Sceneay","year":"2013","journal-title":"Cancer Metastas. Rev."},{"key":"10.1016\/j.jbo.2017.09.001_bib20","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10555-012-9379-3","article-title":"The rejuvenated scenario of epithelial\u2013mesenchymal transition (EMT) and cancer metastasis","volume":"31","author":"Meng","year":"2012","journal-title":"Cancer Metastas. Rev."},{"key":"10.1016\/j.jbo.2017.09.001_bib21","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(00)49915-0","article-title":"The distribution of secondary growths in cancer of the breast","volume":"1","author":"Paget","year":"1889","journal-title":"Lancet"},{"key":"10.1016\/j.jbo.2017.09.001_bib22","doi-asserted-by":"crossref","first-page":"9254","DOI":"10.1038\/s41598-017-10166-8","article-title":"Comparison of patterns and prognosis among distant metastatic breast cancer patients by age groups: a SEER population based analysis","volume":"7","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jbo.2017.09.001_bib23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12885-016-2169-5","article-title":"Distribution and prognosis of uncommon metastases from non-small cell lung cancer","volume":"16","author":"Niu","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jbo.2017.09.001_bib24","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ejso.2006.02.009","article-title":"Expression of the calcium receptor in human breast cancer-a potential new marker predicting the risk of bone metastases","volume":"32","author":"Mihai","year":"2006","journal-title":"Eur. J. Surg. Oncol."},{"key":"10.1016\/j.jbo.2017.09.001_bib25","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.yexcr.2009.03.003","article-title":"Extracellular calcium promotes the migration of breast cancer cells through the activation of the calcium sensing receptor","volume":"315","author":"Saidak","year":"2009","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.jbo.2017.09.001_bib26","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00109-015-1329-4","article-title":"Bone metastasis and the metastatic niche","volume":"93","author":"Ren","year":"2015","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.jbo.2017.09.001_bib27","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2174\/156800909789760348","article-title":"Integrins in bone metastasis formation and potential therapeutic implications","volume":"9","author":"Cl\u00e9zardin","year":"2009","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.jbo.2017.09.001_bib28","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/(SICI)1097-4652(199809)176:3<482::AID-JCP5>3.0.CO;2-K","article-title":"Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the \u03b1v\u03b23 and \u03b1v\u03b25 integrins","volume":"176","author":"Sung","year":"1998","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.jbo.2017.09.001_bib29","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood.V96.5.1953","article-title":"Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and \u03b14\u03b21-integrin enhances production of osteoclast-stimulating activity","volume":"96","author":"Michigami","year":"2000","journal-title":"Blood"},{"issue":"Suppl. 7","key":"10.1016\/j.jbo.2017.09.001_bib30","first-page":"S1","article-title":"The Science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumours","volume":"7","author":"Lipton","year":"2009","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.jbo.2017.09.001_bib31","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.critrevonc.2011.02.005","article-title":"Consensus on the utility of bone markers in the malignant bone disease setting","volume":"80","author":"Coleman","year":"2011","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"10.1016\/j.jbo.2017.09.001_bib32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/BF02967492","article-title":"Evaluation of bone metabolic markers in breast cancer with bone metastasis","volume":"8","author":"Wada","year":"2001","journal-title":"Breast Cancer"},{"key":"10.1016\/j.jbo.2017.09.001_bib33","first-page":"1961","article-title":"Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas","volume":"27","author":"Oremek","year":"2007","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jbo.2017.09.001_bib34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cca.2016.07.005","article-title":"Bone turnover markers in women with early stage breast cancer who developed bone metastases. A prospective study with multivariate logistic regression analysis of accuracy","volume":"460","author":"Lumachi","year":"2016","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jbo.2017.09.001_bib35","article-title":"Validity of osteoprotegerin and receptor activator of NF-\u03baB ligand for detection of bone metastasis in breast cancer","author":"Elfar","year":"2016","journal-title":"Oncol. Res."},{"key":"10.1016\/j.jbo.2017.09.001_bib36","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.juro.2007.05.029","article-title":"Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach","volume":"178","author":"Koopmans","year":"2007","journal-title":"J. Urol."},{"issue":"2","key":"10.1016\/j.jbo.2017.09.001_bib37","first-page":"671","article-title":"Procollagen type-1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma","volume":"29","author":"Klepzig","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.jbo.2017.09.001_bib38","first-page":"89","article-title":"Diagnostic value of some biochemical bone markers for the detection of bone metastases in prostate cancer","volume":"35","author":"Westerhuis","year":"1997","journal-title":"Eur. J. Clin. Chem. Clin. Biochem."},{"key":"10.1016\/j.jbo.2017.09.001_bib39","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.eururo.2016.05.023","article-title":"Decline in circulating tumor cell count and treatment outcome in advanced prostate cancer","volume":"70","author":"Lorente","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.jbo.2017.09.001_bib40","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/1097-0142(20010415)91:8<1487::AID-CNCR1156>3.0.CO;2-2","article-title":"Diagnostic value of bone turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma","volume":"91","author":"Izumi","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2017.09.001_bib41","first-page":"214","article-title":"Beta-CTX and ICTP act as indicators of skeletal metastasis status in male patients with non-small cell lung cancer","volume":"22","author":"Kong","year":"2007","journal-title":"Int. J. Biol. Markers"},{"issue":"Special Issue","key":"10.1016\/j.jbo.2017.09.001_bib42","first-page":"C140","article-title":"Serum bone-specific alkaline phosphatase as a biomarker for osseous metastases in patients with malignant carcinomas: a systematic review and meta-analysis","volume":"10","author":"Du","year":"2014","journal-title":"J. Cancer Res. Ther."},{"issue":"2","key":"10.1016\/j.jbo.2017.09.001_bib43","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/0300060515600187","article-title":"Serum cross-linked N-telopeptide of type I collagen for the diagnosis of bone metastases from solid tumours in the Chinese population: meta-analysis","volume":"44","author":"Zhang","year":"2016","journal-title":"J. Int. Med. Res."},{"issue":"22","key":"10.1016\/j.jbo.2017.09.001_bib44","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers on cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2017.09.001_bib45","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10549-010-0981-1","article-title":"Prognostic factors for skeletal complications from metastatic disease in breast cancer","volume":"123","author":"Brown","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jbo.2017.09.001_bib46","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.clon.2012.11.004","article-title":"Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses","volume":"25","author":"Lipton","year":"2013","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.jbo.2017.09.001_bib47","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumours and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.jbo.2017.09.001_bib48","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1158\/1078-0432.CCR-15-3086","article-title":"Changes in bone turnover marker levels and clinical outcomes in patients with advanced cancer and bone metastases treated with bone antiresorptive agents","volume":"22","author":"Lipton","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbo.2017.09.001_bib49","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jbo.2013.01.002","article-title":"Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features \u2013 an exploratory analysis of placebo-controlled trials","volume":"2","author":"Coleman","year":"2013","journal-title":"J. Bone Oncol."},{"issue":"4","key":"10.1016\/j.jbo.2017.09.001_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/dju013","article-title":"Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421","volume":"106","author":"Lara","year":"2014","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"10.1016\/j.jbo.2017.09.001_bib51","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12885-016-2260-y","article-title":"Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer","volume":"16","author":"Mikah","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jbo.2017.09.001_bib52","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdu544","article-title":"Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozole plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12","volume":"26","author":"Gnant","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbo.2017.09.001_bib53","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","article-title":"AZURE investigators, adjuvant zoledronic acid in patients with early BC: final efficacy analysis of the AZURE (big 01\/04) randomised open- label phase 3 trial","volume":"15","author":"Coleman","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2017.09.001_bib54","doi-asserted-by":"crossref","unstructured":"R. Coleman, M. Gnant, A. Paterson, T. Powles, G. von Minckwitz, K. Pritchard, J. Bergh, J. Bliss, J. Gralow, S. Anderson, V. Evans, H. Pan, R. Bradley, C. Davies, R. Gray, , Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: a meta-analysis of individual patient data from randomized trials, in: Proceedings of San Antonio Breast Cancer Symposium, Abstract S4-07, 2013.","DOI":"10.1158\/0008-5472.SABCS13-S4-07"},{"key":"10.1016\/j.jbo.2017.09.001_bib55","first-page":"547","article-title":"Retrospective analysis of metastatic behavior of breast cancer subtypes","volume":"150","author":"Savci-Heijink","year":"2015","journal-title":"BC Res. Treat."},{"key":"10.1016\/j.jbo.2017.09.001_bib56","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00428-017-2065-7","article-title":"Breast carcinoma subtypes show different patterns of metastatic behavior","volume":"470","author":"Moln\u00e1r","year":"2017","journal-title":"Virchows Arch."},{"key":"10.1016\/j.jbo.2017.09.001_bib57","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S1535-6108(03)00132-6","article-title":"A multigenic program mediating breast cancer metastasis to bone","volume":"3","author":"Kang","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbo.2017.09.001_bib58","first-page":"249","article-title":"A novel gene expression signature for bone metastasis in breast carcinomas","volume":"156","author":"Savci-Heijink","year":"2016","journal-title":"BC Res. Treat."},{"key":"10.1016\/j.jbo.2017.09.001_bib59","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1530\/ERC-13-0158","article-title":"Different molecular profiles are associated with breast cancer cell homing compared with colonization of bone: evidence using a novel bone-seeking cell line","volume":"21","author":"Nutter","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"issue":"46","key":"10.1016\/j.jbo.2017.09.001_bib60","doi-asserted-by":"crossref","first-page":"75571","DOI":"10.18632\/oncotarget.12289","article-title":"IL-1 drives breast cancer growth and bone metastasis in vivo","volume":"7","author":"Holen","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jbo.2017.09.001_bib61","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/path.4882","article-title":"The critical role of the ZNF217 oncogene in promoting breast cancer metastasis to the bone","volume":"242","author":"Bellanger","year":"2017","journal-title":"J. Pathol."},{"issue":"12","key":"10.1016\/j.jbo.2017.09.001_bib62","doi-asserted-by":"crossref","first-page":"djv256","DOI":"10.1093\/jnci\/djv256","article-title":"Enhanced MAF Oncogene Expression and breast cancer Bone Metastasis","volume":"107","author":"Pavlovic","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jbo.2017.09.001_bib63","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature06174","article-title":"Tumour invasion and metastasis initiated by microRNA-10b in breast cancer","volume":"449","author":"Ma","year":"2007","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.jbo.2017.09.001_bib64","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/ncb1681","article-title":"The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis","volume":"10","author":"Huang","year":"2008","journal-title":"Nat. Cell Biol."},{"issue":"50","key":"10.1016\/j.jbo.2017.09.001_bib65","doi-asserted-by":"crossref","first-page":"42084","DOI":"10.1074\/jbc.M112.377515","article-title":"miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells","volume":"287","author":"Hassan","year":"2012","journal-title":"Biol. Chem."},{"key":"10.1016\/j.jbo.2017.09.001_bib66","first-page":"40487","article-title":"Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer","volume":"7","author":"Liu","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jbo.2017.09.001_bib67","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nature06487","article-title":"Endogenous human microRNAs that suppress breast cancer metastasis","volume":"451","author":"Tavazoie","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.jbo.2017.09.001_bib68","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.breast.2016.09.017","article-title":"Breast cancer osteomimicry and its role in bone specific metastasis; an integrative, systematic review of preclinical evidence","volume":"30","author":"Awolaran","year":"2016","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.jbo.2017.09.001_bib69","doi-asserted-by":"crossref","first-page":"465","DOI":"10.5489\/cuaj.117","article-title":"Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: incorporating new agents into clinical practice","volume":"6","author":"So","year":"2012","journal-title":"J. Can. Urol. Assoc."},{"issue":"1","key":"10.1016\/j.jbo.2017.09.001_bib70","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ctrv.2013.07.001","article-title":"Predicting the risk of bone metastasis in prostate cancer","volume":"40","author":"Briganti","year":"2014","journal-title":"Cancer Treat. Rev."},{"issue":"6 Pt 1","key":"10.1016\/j.jbo.2017.09.001_bib71","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1097\/01.ju.0000123981.03084.06","article-title":"Baseline staging of newly diagnosed prostate cancer: a summary of the literature","volume":"171","author":"Abuzallouf","year":"2004","journal-title":"J. Urol."},{"issue":"45","key":"10.1016\/j.jbo.2017.09.001_bib72","doi-asserted-by":"crossref","first-page":"6848","DOI":"10.1038\/sj.onc.1208815","article-title":"Bone-metastatic potential of human prostate cancer cells correlates with Akt\/PKB activation by \u03b1 platelet-derived Growth factor receptor","volume":"24","author":"Dolloff","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.jbo.2017.09.001_bib73","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/onc.2008.390","article-title":"The \u03b1-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells","volume":"28","author":"Russell","year":"2009","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.jbo.2017.09.001_bib74","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1158\/0008-5472.CAN-12-3970","article-title":"Interleukin-1\u03b2 promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features","volume":"73","author":"Liu","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbo.2017.09.001_bib75","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.2147\/DDDT.S82475","article-title":"The association of CXCR4 expression with clinic-pathological significance and potential drug target in prostate cancer: a meta-analysis and literature review","volume":"9","author":"Chen","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"issue":"24","key":"10.1016\/j.jbo.2017.09.001_bib76","doi-asserted-by":"crossref","first-page":"6559","DOI":"10.1158\/1078-0432.CCR-14-1784","article-title":"miR-154 and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancer","volume":"20","author":"Gururajan","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.jbo.2017.09.001_bib77","doi-asserted-by":"crossref","first-page":"e20341","DOI":"10.1371\/journal.pone.0020341","article-title":"Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT","volume":"6","author":"Peng","year":"2011","journal-title":"PLoS One"},{"issue":"16","key":"10.1016\/j.jbo.2017.09.001_bib78","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1158\/1078-0432.CCR-10-2619","article-title":"Regulatory role of mir-203 in prostate cancer progression and metastasis","volume":"17","author":"Saini","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"19","key":"10.1016\/j.jbo.2017.09.001_bib79","doi-asserted-by":"crossref","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","article-title":"Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer","volume":"14","author":"de Bono","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.jbo.2017.09.001_bib80","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.1158\/1078-0432.CCR-07-1506","article-title":"Circulating tumour cell number and prognosis in progressive castration-resistant prostate cancer","volume":"13","author":"Danila","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jbo.2017.09.001_bib81","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/annonc\/mdn544","article-title":"Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience","volume":"20","author":"Olmos","year":"2009","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.jbo.2017.09.001_bib82","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1470-2045(08)70340-1","article-title":"Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data","volume":"10","author":"Scher","year":"2009","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.jbo.2017.09.001_bib83","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1200\/JCO.2013.51.7417","article-title":"Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer","volume":"32","author":"Goldkorn","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 15","key":"10.1016\/j.jbo.2017.09.001_bib84","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.1200\/jco.2015.33.15_suppl.5035","article-title":"Circulating tumor cell (CTC) enumeration in men with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide post-chemotherapy (phase 3 AFFIRM study)","volume":"33","author":"Fleisher","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2017.09.001_bib85","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s002590050430","article-title":"Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients","volume":"26","author":"Lorente","year":"1999","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/j.jbo.2017.09.001_bib86","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00432-013-1377-5","article-title":"Detection of circulating tumor cells in different stages of prostate cancer","volume":"139","author":"Thalgott","year":"2013","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.jbo.2017.09.001_bib87","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.3390\/ijms17122008","article-title":"Epidermal growth factor receptor status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with docetaxel chemotherapy","volume":"17","author":"Okegawa","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbo.2017.09.001_bib88","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jbo.2017.09.001_bib89","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4103\/0973-1482.200597","article-title":"Screening of gene mutations associated with bone metastasis in non small cell lung cancer","volume":"12","author":"Zhang","year":"2016","journal-title":"J. Can. Res. Ther."},{"key":"10.1016\/j.jbo.2017.09.001_bib90","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1200\/JCO.2006.06.1952","article-title":"Bone sialoprotein is predictive of bone metastases in resectable non small cell lung cancer: a retrospective case-control study","volume":"24","author":"Papotti","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"34","key":"10.1016\/j.jbo.2017.09.001_bib91","first-page":"1","article-title":"Establishment of a biomarker model for predicting bone metastasis in resected stage III non small cell lung cancer","volume":"31","author":"Zhou","year":"2012","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.jbo.2017.09.001_bib92","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/cncr.10828","article-title":"Parathyroid hormone-related protein measured at the time of first visit is an indicator of bone metastases and survival in lung carcinoma patients with hypercalcemia","volume":"95","author":"Hiraki","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.jbo.2017.09.001_bib93","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1016\/j.bbagen.2013.02.022","article-title":"MicroRNA-33a functions as a bone metastasis suppressor in lung cancer by targeting parathyroid hormone related protein","volume":"1830","author":"Kuo","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"issue":"9","key":"10.1016\/j.jbo.2017.09.001_bib94","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1200\/JCO.2010.32.5209","article-title":"American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer","volume":"29","author":"Van Poznak","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbo.2017.09.001_bib95","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.ctrv.2015.09.003","article-title":"Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implications","volume":"41","author":"D\u2019Oronzo","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jbo.2017.09.001_bib96","article-title":"The value of biomarkers in bone metastasis","author":"D\u2019Oronzo","year":"2017","journal-title":"Eur. J. Cancer Care"},{"issue":"1","key":"10.1016\/j.jbo.2017.09.001_bib97","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumours","volume":"97","author":"Brown","year":"2005","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137417300775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137417300775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:16:31Z","timestamp":1761941791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137417300775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":97,"alternative-id":["S2212137417300775"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2017.09.001","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of biomarkers in the management of bone-homing malignancies","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2017.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}]}}